Tela Bio Inc (TELA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$0.82+5.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · TELA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on improving OviTex PRS performance, accelerating hernia market share gains, and translating commercial productivity into sustainable top-line growth.
Stated as a priority in 2 of last 2 quarters. Revenue grew 3% from $18.5M in 2025-Q1 to $19.1M in 2026-Q1 but declined 4% to $19.3M in 2026-Q2 from $20.2M in 2025-Q2. Management emphasizes improving PRS performance and hernia market share to return to growth in H2 2026. The trajectory shows mixed results with growth in Q1 but decline in Q2, indicating limited progress so far.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Focus on returning to growth in the second half the year by improving PRS performance and accelerating market share gains in hernia.”
“Positioned well to deliver predictable growth through the remainder of 2026.”
Implement cost reduction initiative including approximately 20% workforce reduction to strengthen cost structure and extend cash runway into 2028.
Newly stated in 2026-Q3. Management announced a $17 million annual operating expense reduction initiative via a 20% workforce cut to improve cost structure and extend cash runway into 2028. Operating expenses remained flat at $23.2 million in 2026-Q2 versus 2025-Q2, indicating limited progress in expense reduction as of the latest quarter.
“Implementing a broader initiative to reduce annual operating expenses by $17 million with a 20% workforce reduction.”
Grow international revenue with continued momentum in European markets including the U.K. and new geographies.
Stated in 2 of last 2 quarters. Management reported international revenue growth of 26% in 2026-Q2 and 41% in 2026-Q1 over prior year periods, driven by European market expansion including the U.K. The trajectory shows delivering growth in international sales consistent with stated priorities.
“Delivered international revenue growth of 26% over the prior year period with momentum in European markets.”
“Accelerated European revenue growth to 41% over prior year period with momentum in U.K. and new European markets.”
Complete the U.S. commercial launch of OviTex LTR, a fully resorbable tissue-based hernia repair solution.
Newly stated in 2026-Q1. Management announced the U.S. commercial launch of OviTex LTR. No specific revenue or volume milestones reported yet, indicating early stage of commercialization with limited substantive delivery so far.
“Initiated the full U.S. commercial launch of OviTex LTR, a fully resorbable tissue-based hernia repair solution.”
Ensure the U.S. commercial sales team is fully staffed to support 2026 growth targets and ramp new territory managers.
Newly stated in 2026-Q1. Management reported the U.S. commercial team is fully staffed at planned levels with new territory managers ramping. No subsequent updates or changes reported, indicating a stable staffing situation consistent with the stated priority.
“The U.S. commercial organization is fully staffed at planned 2026 levels with new reps ramping as expected.”
Over the trailing year it converted 1.10x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.